Skip to main content
TipRanks
Go Ultimate75% OFF

Hikal Limited (HIKAL) AI Stock Analysis

2 Followers
IN:HIKAL

Hikal Limited

(NSE:HIKAL)

Select Model
Rating:53Neutral
Price Target:INR 221.00â–¼(-0.38% Downside)
Action:reiterated
Date:09/08/26

The overall score is held back mainly by weak recent financial performance: revenue stagnation, a move to net loss, and choppy free cash flow create meaningful earnings and execution risk despite a conservative, low-debt balance sheet that provides a safety cushion. Valuation looks unappealing with a negative P/E and low dividend yield, offering limited compensation for these risks. Technicals are a relative bright spot, with the price above key moving averages and neutral momentum indicators, indicating an improving trend but not enough strength to outweigh the fundamental and valuation concerns.

Positive Factors
Specialty chemicals and CDMO platformHikal combines specialty chemicals manufacturing with contract development and manufacturing services across pharmaceutical and crop-protection markets. Its process development and scale-up capabilities can support repeat customer relationships and create durable relevance across regulated and non-regulated applications.
Negative Factors
Recent loss-making profitabilityThe latest swing to a net loss weakens earnings quality and reduces confidence in near-term profit durability. It indicates that gross profit is currently insufficient to absorb operating costs or other pressures, leaving future cash allocation and investment decisions more dependent on recovery.

Hikal Limited (HIKAL) vs. iShares MSCI India ETF (INDA)

-40%-30%-20%-10%0%10%20%IN:HIKAL+1.94%INDA-4.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 27.79B
Dividend Yield
0.27%
Average Volume (3M)
75.63K
Price to Earnings (P/E)
-555.1
Beta (1Y)
1.06
Revenue Growth
8.93%
EPS Growth
-149.51%
Country
India
Employees
3,595
Sector
General
Sector Strength
55
Industry
Medical - Pharmaceuticals

Hikal Limited Business Overview & Revenue Model

Company Description

Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty ch...

Hikal Limited Financial Statement Overview

Summary

Financials are mixed: a strong, low-leverage balance sheet and consistent operating cash generation are offset by flat-to-declining revenue, a swing to net loss in 2026, and volatile free cash flow, indicating elevated execution and earnings risk despite a solid capital base.

Income Statement

38Negative

Balance Sheet

72Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue18.51B17.13B18.60B17.69B20.05B19.26B
Gross Profit5.65B5.17B10.22B9.05B8.62B8.83B
EBITDA2.29B1.48B3.33B2.67B2.60B3.40B
Net Income-50.00M-488.00M908.00M696.02M783.82M1.60B
Balance Sheet
Total Assets23.41B23.65B25.29B24.87B23.85B22.13B
Cash, Cash Equivalents and Short-Term Investments228.00M136.00M178.00M181.93M267.30M217.09M
Total Debt6.39B6.84B7.65B8.18B7.48B6.75B
Total Liabilities11.60B11.67B12.67B12.99B12.52B11.45B
Stockholders Equity11.81B11.99B12.62B11.88B11.33B10.68B
Cash Flow
Free Cash Flow0892.00M1.43B-174.80M126.89M204.19M
Operating Cash Flow793.00M2.37B2.80B1.87B3.15B2.94B
Investing Cash Flow-809.00M-1.46B-1.36B-1.74B-2.92B-2.84B
Financing Cash Flow-22.00M-943.00M-1.44B-270.00M-76.80M-55.58M

Hikal Limited Technical Analysis

Technical Analysis SentimentPositive
Last Price221.85

Price Trends

50DMA218.86Positive
100DMA219.56Positive
200DMA204.80Positive

Market Momentum

MACD2.06Negative
RSI54.21Neutral
STOCH48.56Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:HIKAL, the sentiment is Positive. The current price of 221.85 is above the 20-day moving average (MA) of 214.24, above the 50-day MA of 218.86, and above the 200-day MA of 204.80, indicating a bullish trend. The MACD of 2.06 indicates Negative momentum. The RSI at 54.21 is Neutral, neither overbought nor oversold. The STOCH value of 48.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:HIKAL.

Hikal Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:HIKAL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:SUPRIYAIN:SUPRIYA66NeutralINR 50.26B28.40―0.16%23.00%-2.84%
IN:ROSSARIIN:ROSSARI65NeutralINR 23.69B15.52―0.12%19.76%11.74%
IN:WOCKPHARMAIN:WOCKPHARMA62NeutralINR 355.33B86.72――25.70%―
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:DCALIN:DCAL55NeutralINR 18.59B27.25――-0.11%-184.93%
IN:HIKALIN:HIKAL53NeutralINR 27.35B-555.15―0.27%8.93%-149.51%
IN:SOLARAIN:SOLARA50NeutralINR 30.74B82.98――27.30%456.80%

* General Sector Average

Performance Comparison

-50%0%50%IN:HIKALIN:DCALIN:ROSSARIIN:SOLARAIN:SUPRIYAIN:WOCKPHARMADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:HIKAL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:HIKALHikal Limited221.85-2.66-1.19%
IN:DCALDishman Carbogen Amcis Ltd.118.60-118.45-49.97%
IN:ROSSARIRossari Biotech Ltd427.75-187.25-30.45%
IN:SOLARASolara Active Pharma Sciences Ltd.639.3093.1017.05%
IN:SUPRIYASupriya Lifescience Limited624.45-118.42-15.94%
IN:WOCKPHARMAWockhardt Limited2186.60874.6066.66%

Hikal Limited Corporate Events

Hikal’s Bengaluru API Plant Secures Swissmedic GMP Nod, Bolstering Global Reach

Oct 30, 2026

Hikal Limited has announced that its active pharmaceutical ingredient facility in Bengaluru has received a Certificate of GMP Compliance from Swissmedic, confirming adherence to European Union–Switzerland mutual recognition standards. This certificat...

Hikal Schedules Analyst and Investor Visit to Pune R&T Centre

Sep 2, 2026

Hikal Limited has scheduled an in-person group meeting for analysts and institutional investors at its Pune research and technology centre on September 4, 2026, starting at 12:00 p.m. IST. The visit will include interactions with company officials, w...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 07, 2026